A cross-sectional study was conducted between April 2023 and August 2023 at three centers specializing in vertigo and dizziness located in Mexico City, Guadalajara, and Medellín. Patients diagnosed with vestibular disorders according to the Barany Society criteria were recruited for the study. During consultations, patients were administered the EQ-5D-3L, visual analogue scale (EQ VAS) and Dizziness Handicap Inventory (DHI) questionnaires. An informed consent was obtained from all participants. This study received approval from the Institutional Review Board (IRB) of Universidad Pontificia Bolivariana, which oversees all three centers.
The EQ-5D-3L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension offers three levels: no problems, some problems, and extreme problems. Patients were asked to indicate their health state by selecting the most appropriate statement within each of the five dimensions. This selection resulted in a one-digit number that represented the chosen level for that dimension. These five digits were then combined into a five-digit number to describe the patient's overall health state (4).
The Dizziness Handicap Inventory (DHI) stands out as one of the widely utilized questionnaires for evaluating the impact of dizziness (6). Originally crafted by Jacobson and Newman, the DHI serves as a tool to gauge the level of disability (6). Comprising 25 items, it aims to discern dizziness-related alterations and categorizes them into three domains: Functional, emotional, and physical. It's worth noting that in certain studies examining patients with vestibular issues, adaptations to these domains have been observed, differing from the original structure (6).
Classification of vestibular syndromes
We classified all included patients into five categories based on the International Classification from the Bárány Society and predefined criteria: (1) acute, (2) episodic and (3) chronic vestibular syndrome, (4) acute imbalance syndrome and (5) patients not classifiable (unclear). (6–13) We defined vestibular syndromes below.
Acute Vestibular Syndrome (AVS): Defined as an acute onset of continuous dizziness lasting days to weeks.
Typically includes symptoms suggestive of new or ongoing dysfunction in the vestibular system, such as vomiting, nystagmus, and severe postural instability.
While AVS is characterized by a single, monophasic event due to a one-time disorder, it may also be the start of a recurrent or progressive illness.
Subclassifications of AVS include t-AVS (postexposure dizziness after trauma or toxic exposure) and s-AVS (spontaneous AVS), which includes patients with continuous dizziness at rest. For simplicity, all these cases are grouped under the term AVS (6–13).
Episodic Vestibular Syndrome (EVS):
Characterized by transient dizziness lasting seconds to hours, rarely days. Accompanied by short episodes of nausea, nystagmus, and sudden falls. EVS can occur repetitively due to episodic disorders with repeated spells or as a single event in progressive chronic disorders with transient or recurrent dizziness. Subtypes of EVS include t-EVS (triggered by specific events) and s-EVS (spontaneous EVS). Diagnosis of s-EVS relies mainly on the patient's history, while t-EVS often presents with clinical signs like positional nystagmus after provocation (6–13).
Chronic Vestibular Syndrome (CVS):
Typically persists for months to years. Associated with continuous dysfunction in the vestibular system, leading to symptoms such as oscillopsia, nystagmus, gait unsteadiness, and falls (6–13).
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, with the endpoints labeled as 'Best imaginable health state' and 'Worst imaginable health state.' The VAS serves as a quantitative measure of health outcome that reflects the patient's own judgment. Statistical analysis was conducted using GraphPad 9.0 (San Diego, CA). A t-test was applied, and linear regression was utilized for the correlational analysis between EQ5D and VAS scores.